Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of CP-4055 (ELACYT) as Second-Line Therapy in Advanced Colorectal Cancer
2006-006766-41Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine in colorectal cancer (CRC), sponsored by Clavis Pharma. Primary endpoint: Objective tumor response (CR + PR) by RECIST. Started Jan 2007; status: completed.
02
Drugs
elacytarabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-006766-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006766-41.